Skip to content

Geron GERN Net Change in Cash

Net Change in Cash at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$635M-220%
Incyte logo
IncyteINCY
$363.28M+43.1%
Immunome logo
ImmunomeIMNM
-$70.79M-162%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$4.04M-4,386%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$21M-150%
Celcuity logo
CelcuityCELC
-$20.51M-240%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-8.6%
Enterprise value$973.78M-6.2%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's net change in cash?
Geron (GERN) reported net change in cash of -$8.66M in Q1 2026.
How has Geron's net change in cash changed year-over-year?
Geron's net change in cash decreased by 283.0% year-over-year, from $4.73M to -$8.66M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.